Skip to main content
Terug
Watch Compare

Acurx Pharmaceuticals, Inc.

Datakwaliteit: 83%
ACXP
NASDAQ Manufacturing Chemicals
€ 2,80
▲ € 0,19 (7,28%)
Marktkapitalisatie: 7,66 M
Prijs
€ 2,68
Marktkapitalisatie
7,66 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -6,79 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-221,19%
Onder sectorgemiddelde (-54,01%)
ROIC-178,80%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current RatioN/A
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-0,96 | -1,19
Boven sectorgemiddelde (-1,49)
P/B Ratio2,11
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -1,0 -1,5
P/B 2,1 1,6
ROE % -221,2 -54,0
Net Margin % — -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 2,80
+507.1%
Koersdoel
€ 17,00
€ 10,00
€ 10,00
€ 31,00
Vooruitzicht
Forward K/W -1,19
Forward WPA -€ 2,20
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 2,20
-€ 2,55 – -€ 1,85
 0,0 2
FY2026 -€ 2,39
-€ 2,68 – -€ 2,10
 0,0 2

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 1,00 -€ 0,31 +68,8%
Q32025 -€ 1,49 -€ 1,23 +17,2%
Q22025 -€ 2,10 -€ 1,89 +10,0%
Q12025 -€ 2,80 -€ 2,20 +21,4%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7,97 M
ROE -221,19% ROA -130,49%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,79 M
ROIC -178,80% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio N/A
Interest Coverage N/A Asset Turnover N/A
Working Capital N/A Tangible Book Value 3,64 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,96 Forward P/E -1,19
P/B Ratio 2,11 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -88,65%
Market Cap 7,66 M Enterprise Value 7,66 M
Per Share
EPS (Diluted TTM) -5,32 Revenue / Share N/A
FCF / Share -2,38 OCF / Share -2,38
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 85,20%
SBC-Adj. FCF -8,09 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7,97 M -14,10 M -14,58 M -12,09 M -12,75 M
EPS (Diluted) -5,32 -0,87 -1,15 -1,12 -1,49
Gross Profit — — — — —
Operating Income -8,09 M — — — —
EBITDA — — — — —
R&D Expenses 1,83 M 5,40 M 6,04 M 4,75 M 2,03 M
SG&A Expenses — — — — 208.270,0
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — 0,0 0,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 7,69 M 3,86 M 7,71 M 9,38 M 13,25 M
Total Liabilities 2,42 M 3,24 M 3,04 M 2,06 M 843.909,0
Shareholders' Equity 5,27 M 615.121,0 4,67 M 7,32 M —
Total Debt — — — — —
Cash & Equivalents — — — — —
Current Assets — — — — —
Current Liabilities 2,42 M 3,24 M 3,04 M 2,06 M 843.909,0